Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
FDA claims on COVID-19 vaccine safety are unsupported by reliable data – and could severely hinder vaccine access - 2Why is everyone talking about Paul Dano? George Clooney becomes the actor's latest defender in this 'time of cruelty.'
- 3The Best Music Collections of the 10 years
- 4Expert advice for new stargazers: How to begin your amateur astronomy journey
- 5A few Exemplary Chinese Dishes, Which Are Famous Around the world
- Study reveals how fast weight returns after ending GLP-1 drugs
- Eurovision Song Contest changes voting rules after controversial allegations against Israel
- Which Store is Your Decision ?
- Italian court approves extradition to Germany of Ukrainian suspect in Nord Stream pipeline blast
- Instructions to Pick the Right Dental Embed Trained professional: An Exhaustive Aide
- Change Your Skincare: 10 Inventive Magnificence Gadgets
- Vote in favor of your Favored kind of craftsmanship
- Moon-bound Artemis II astronauts enjoy a relaxed day in space
- The most effective method to Go Down Abundance through Ages with Disc Rates
